BRPI1013992A2 - compositions and methods for treating insulin resistance and diabetes mellitus - Google Patents

compositions and methods for treating insulin resistance and diabetes mellitus

Info

Publication number
BRPI1013992A2
BRPI1013992A2 BRPI1013992A BRPI1013992A BRPI1013992A2 BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2 BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
diabetes mellitus
insulin resistance
treating insulin
Prior art date
Application number
BRPI1013992A
Other languages
Portuguese (pt)
Inventor
Anthony B Wood
Gregory J Archambeau
Richard L Watson
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of BRPI1013992A2 publication Critical patent/BRPI1013992A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1013992A 2009-04-27 2010-04-27 compositions and methods for treating insulin resistance and diabetes mellitus BRPI1013992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication Number Publication Date
BRPI1013992A2 true BRPI1013992A2 (en) 2016-08-16

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013992A BRPI1013992A2 (en) 2009-04-27 2010-04-27 compositions and methods for treating insulin resistance and diabetes mellitus

Country Status (9)

Country Link
EP (1) EP2424507A4 (en)
JP (2) JP2012525396A (en)
CN (1) CN102413817B (en)
AU (1) AU2010241736B2 (en)
BR (1) BRPI1013992A2 (en)
CA (1) CA2758738A1 (en)
IL (1) IL215925A0 (en)
MX (1) MX2011011333A (en)
WO (1) WO2010126908A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (en) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphs of 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
CN103209664A (en) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 implantable therapeutic device
JP2013533320A (en) 2010-08-12 2013-08-22 レバレジオ コーポレイション Compositions and methods for treating tauopathy
PT2640371T (en) * 2010-11-15 2020-04-17 Boehringer Ingelheim Int Vasoprotective and cardioprotective antidiabetic therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CN103561722A (en) * 2011-04-13 2014-02-05 利发利希奥公司 Compositions and methods for inhibiting and/or modulating effector T cells involved in inflammatory neurodegenerative diseases
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
PT2755600T (en) 2011-09-16 2021-04-19 Forsight Vision4 Inc Fluid exchange apparatus and methods
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6218811B2 (en) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for use in the treatment of SIRS and / or sepsis
JP6159584B2 (en) * 2012-06-14 2017-07-05 松本　高明 Infusion, infusion production method and infusion device
CH706747A2 (en) * 2012-07-17 2014-01-31 Hanspeter Steffen Process for hydration, tightening and care of the skin, for the treatment of dermatoses, sunburn and general wounds with electrolysis water produced with diamond electrodes.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246438B (en) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 Ophthalmic implants for delivery of therapeutic substances
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
WO2015099201A1 (en) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Nanobubble-containing composition and use thereof
ES2803102T3 (en) 2014-07-15 2021-01-22 Forsight Vision4 Inc Eye implant delivery device
RU2017105844A (en) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Stable and soluble compositions of receptor tyrosine kinase inhibitors and methods for their preparation
CN110478119B (en) 2014-11-10 2022-04-15 弗赛特影像4股份有限公司 Expandable drug delivery device and method of use
JP6674748B2 (en) * 2015-05-27 2020-04-01 花王株式会社 GLP-1 secretagogue
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
CN113017981B (en) 2016-04-05 2023-07-25 弗赛特影像4股份有限公司 drug delivery device
CN105878194A (en) * 2016-06-07 2016-08-24 沈阳药科大学 Glibenclamide nanocrystal preparation and preparation method thereof
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 Combination of linagliptin and metformin
CN106362166B (en) * 2016-10-27 2019-12-10 武汉大学 Function and application of tumor necrosis factor receptor-related pan-scaffold and signaling protein in treatment of fatty liver and type II diabetes
CN111655206B (en) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 Fluid exchange device for expandable port delivery system and method of use
CN110006871A (en) * 2019-02-20 2019-07-12 常州大学 A cellular model based on exogenous histamine detection and its application
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (en) * 1990-10-02 1992-04-16 Buchholz Klaus L Use of the reaction product of a gas and a liquid, as well as process and device for producing the same
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
JP2004529090A (en) * 2001-02-01 2004-09-24 ハイドロン テクノロジーズ，インク． Hyperoxygenated compositions and methods for supplying oxygen to tissue
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7347944B2 (en) * 2005-06-03 2008-03-25 BAGLEY David Method for making and conditioning super-oxygenated and structured water
JP5306214B2 (en) * 2006-10-25 2013-10-02 リバルシオ コーポレイション Mixing equipment
CA2667791A1 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (en) * 2006-12-26 2008-07-10 Hydrox Kk Antioxidant functional water
CA2703672A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Also Published As

Publication number Publication date
EP2424507A4 (en) 2012-10-24
EP2424507A1 (en) 2012-03-07
AU2010241736B2 (en) 2016-01-28
MX2011011333A (en) 2011-11-18
CN102413817B (en) 2014-12-17
CA2758738A1 (en) 2010-11-04
IL215925A0 (en) 2011-12-29
WO2010126908A1 (en) 2010-11-04
CN102413817A (en) 2012-04-11
JP2015229678A (en) 2015-12-21
JP2012525396A (en) 2012-10-22
AU2010241736A1 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
BRPI1013992A2 (en) compositions and methods for treating insulin resistance and diabetes mellitus
NO2024044I1 (en) Insulin icodec
BRPI0910282A2 (en) Oxadiazo-anthracene compound for diabetes treatment
HUE038279T2 (en) Clotho-beta agonist antibody for use in the treatment of diabetes or insulin resistance
BRPI0716134A2 (en) combination treatment for diabetes mellitus
BRPI1012642A2 (en) insulin formulation and method for treating a diabetic individual.
DK2252312T3 (en) Methods for preventing or treating insulin resistance
BRPI0911782A2 (en) super fast acting insulin composition
FI20096188A0 (en) Nutrigenetic biomarkers for obesity and type 2 diabetes
BRPI1006145A2 (en) "composition and method for treating diabetes".
BRPI0908416A2 (en) Injection Syringe
EP2367541A4 (en) CONTROLLED RELEASE COMPOSITION PREVENTING MISUSE
EP2409997A4 (en) REDOX CURED TYPE COMPOSITION
DK3181134T3 (en) BIFIDOBACTERIA FOR TREATING DIABETES AND RELATED CONDITIONS
IL205554A (en) Composition for treating insulin resistance comprising melanocortins
BRPI0813909A2 (en) Syringe with Disable Mechanism
BRPI0815760A2 (en) INJECTABLE DERMATOLOGICAL COMPOSITION FOR WRINKLE TREATMENT
BR112012000502A2 (en) combination therapy for diabetes treatment
BRPI0919288A2 (en) combination therapy for treatment of diabetes and related conditions.
BRPI0822830A2 (en) Disable mechanism syringe
BRPI0906094A2 (en) Type II Diabetes Compound and Treatment Method
BRPI0810525A2 (en) COMPOSITIONS AND METHODS FOR PROPHYLAXY AND CHEMICAL DEPENDENCE TREATMENT
BRPI0911083A8 (en) methods for treating or preventing diabetes mellitus and other metabolic imbalances
SI2403605T1 (en) Compositions comprising an aP2-specific antibody or a fragment thereof for use in treating diabetes, glucose intolerance or obesity-induced insulin resistance
BR112012006437A2 (en) compositions and methods for treating diabetes and other disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]